drugset / Trial / NCT03423446
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the effect of severe hepatic impairment on the pharmacokinetics (PK) of telotristat ethyl (TE) ( LP-778902 active moiety, metabolite), following administration of a single dose of TE 250 mg (1 x 250-mg tablet) compared to healthy, demographically-matched subjects with normal hepatic function.
Timeline
- Start
- 2017-11-28
- Primary completion
- 2018-06-15
- Completion
- 2018-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telotristat Ethyl | Unknown | 250 mg | — |
Indications
No indication recorded.